163 related articles for article (PubMed ID: 38099944)
61. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
Nandula SR; Kundu N; Awal HB; Brichacek B; Fakhri M; Aimalla N; Elzarki A; Amdur RL; Sen S
Cardiovasc Diabetol; 2021 Feb; 20(1):44. PubMed ID: 33581737
[TBL] [Abstract][Full Text] [Related]
62. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
63. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Liao J; Kang A; Xia C; Young T; Di Tanna GL; Arnott C; Pollock C; Krishnan AV; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B
Diabetes Metab; 2022 Jul; 48(4):101331. PubMed ID: 35172198
[TBL] [Abstract][Full Text] [Related]
64. Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review.
Kruger D; Valentine V
Diabetes Ther; 2020 Jun; 11(6):1237-1250. PubMed ID: 32405876
[TBL] [Abstract][Full Text] [Related]
65. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL
J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099
[TBL] [Abstract][Full Text] [Related]
66. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
67. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ
Diabetes Obes Metab; 2023 Aug; 25(8):2151-2162. PubMed ID: 37161691
[TBL] [Abstract][Full Text] [Related]
68. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
69. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
Ferrannini G; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Cardiovasc Diabetol; 2023 Apr; 22(1):100. PubMed ID: 37120538
[TBL] [Abstract][Full Text] [Related]
70. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
[TBL] [Abstract][Full Text] [Related]
71. Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
Neumiller JJ; Rhee CM; Kalantar-Zadeh K
Am J Nephrol; 2017; 46(6):459-461. PubMed ID: 29227973
[No Abstract] [Full Text] [Related]
72. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
73. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
[TBL] [Abstract][Full Text] [Related]
74. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
Wada T; Mori-Anai K; Takahashi A; Matsui T; Inagaki M; Iida M; Maruyama K; Tsuda H
J Diabetes Investig; 2022 Dec; 13(12):1981-1989. PubMed ID: 35861630
[TBL] [Abstract][Full Text] [Related]
75. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
76. Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial.
Greeviroj P; Puapatanakul P; Phannajit J; Takkavatakarn K; Kittanamongkolchai W; Boonchaya-Anant P; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Clin Nephrol; 2023 Nov; 100(5):224-230. PubMed ID: 37675488
[TBL] [Abstract][Full Text] [Related]
77. How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?
Neumiller JJ; Kalyani RR
Clin J Am Soc Nephrol; 2019 Nov; 14(11):1667-1669. PubMed ID: 31575617
[No Abstract] [Full Text] [Related]
78. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
79. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
80. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
